Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma

  • 45 Accesses

  • 10 Citations

Summary

A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1–5 as 2-h infusions, 1.5 mg/m2 vincristine given on day 1 as a bolus injection, 50 mg/m2 doxorubicin given on day 1 as a 5-min infusion, and 250 mg/m2 dacarbazine given daily on days 1–5 as 30-min infusions). The overall response rate in 24 patients who were evaluable for response was 46% [95% confidence interval (CI), 25%–67%] and that in subjects who had not undergone prior chemotherapy was 50% (CI, 27%–73%). In all, 4 patients achieved a complete response (17%; CI, 5%–37%) and 2 remain in remission; 3 additional subjects were surgically rendered disease-free after they had shown a partial response. Overall, 31 patients were evaluable for toxicity. Toxicity was mainly hematological; in 3 patients the nadir WBC was <0.5×109/l, and in 2 cases the nadir platelet count was <50×109/l. During neutropenia, infections requiring intravenous antibiotics occurred in 8 patients (26%) and in 14 of 190 cycles (7.5%); 1 of these was fatal. We conclude that this new regimen offers promise for the treatment of advanced STS, producing acceptable toxicity.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Antman KH, Ryan L, Elias A, Sherman D, Grier HE (1989) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126

  2. 2.

    Blomqvist C, Wiklund T, Miettinen M, Elomaa I (1990) Low activity of alternating chemotherapy regimen (ifosfamide-etoposide +epirubicin-DTIC) in advanced soft tissue sarcoma (abstract). Ann Oncol 1 [Suppl]:97

  3. 3.

    Blum RH (1975) An overview of studies with Adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6:247

  4. 4.

    Bodey GP, Rodriguez V, Murphy WK, Burgess A, Benjamin RS (1981) Protected environment-prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Cancer 47:2422

  5. 5.

    Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP (1987) Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5:840

  6. 6.

    Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Oosterom A van (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311

  7. 7.

    Bramwell VH, Quirt I, Warr D, Verma S, Young V, Knowling M, Eisenhauer E (1989) Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. J Natl Cancer Inst 81:1496

  8. 8.

    Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet II:657

  9. 9.

    Cantwell BM, Carmichael J, Ghani S, Harris AL (1988) A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol 21:49

  10. 10.

    Edmonson J, Blum R, Ryan I, Shiraki M, Parkinson D (1991) Phase III Eastern Cooperative Oncology Group study of ifosfamide +doxorubicin versus mitomycin+doxorubicin+cisplatin versus doxorubicin alone against soft tissue sarcomas (abstract). Proc Am Soc Clin Oncol: 353

  11. 11.

    Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH (1989) Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7:1208

  12. 12.

    Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9:14

  13. 13.

    Loehrer PS, Sledge GJ, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, Omura G, Braun TJ (1989) Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 7:1655

  14. 14.

    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207

  15. 15.

    Pinedo HM, Kenis Y (1977) Chemotherapy of advanced soft-tissue sarcomas in adults. Cancer Treat Rev 4:67

  16. 16.

    Pinedo HM, Bramwell VH, Mouridsen HT, Somers R, Vendrik CP, Santoro A, Buesa J, Wagener T, Oosterom AT van, Unnik JAM van, Sylvester R, Pauw M de, Thomas D, Bonadonna G (1984) Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 53:1825

  17. 17.

    Rosenberg SA, Suit HD, Baker LH (1985) Sarcomas of soft tissue. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. J. B. Lippincott, Philadelphia, p 1243

  18. 18.

    Santoro A, Rouessé J, Steward W, Mouridsen H, Verweij J, Somers R, Blackledge G, Buesa J, Sayer H, Thomas D, Sylvester R (1989) A randomized EORTC study in advanced soft tissue sarcomas (STS): ADM vs ADM+IFX vs CYVADIC (abstract). Proc ECCO 5: 0–0438

  19. 19.

    Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC (1982) A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50:2757

  20. 20.

    Schutte J, Mouridsen HT, Stewart W, Santoro A, Oosterom AT van, Somers R, Blackledge G, Verweij J, Dombernowsky P, Thomas D, Sylvester R (1990) Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 26:558

  21. 21.

    Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E (1983) High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 10 [Suppl A]:163

  22. 22.

    Subramanian S, Wiltshaw E (1978) Chemotherapy of sarcoma. A comparison of three regimens. Lancet I:683

  23. 23.

    Yap BS, Baker LH, Sincovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP (1980) Cyclophosphamide, vincristine, Adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93

  24. 24.

    Yap BS, Sincovics JG, Burgess MA, Benjamim RS, Bodey GP (1983) The curability of advanced soft tissue sarcomas in adults with chemotherapy (abstract) Proc Am Soc Clin Oncol: 239

Download references

Author information

Correspondence to Tom A. Wiklund.

Additional information

This study was supported in part by grants from Finska Läkaresällskapet (Finnish Medical Society)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wiklund, T.A., Blomqvist, C.P., Virolainen, M. et al. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. Cancer Chemother. Pharmacol. 30, 100–104 (1992). https://doi.org/10.1007/BF00686400

Download citation

Keywords

  • Doxorubicin
  • Neutropenia
  • Cyclophosphamide
  • Vincristine
  • Bolus Injection